2008
Quantitative in Situ Assessment of the Somatostatin Receptor in Breast Cancer to Assess Response to Targeted Therapy with 111-in-Pentetreotide. Addendum
Chung G, Rimm D. Quantitative in Situ Assessment of the Somatostatin Receptor in Breast Cancer to Assess Response to Targeted Therapy with 111-in-Pentetreotide. Addendum. 2008 DOI: 10.21236/ada487987.Peer-Reviewed Original ResearchBreast cancerTissue microarrayPredominant receptor subtypeWhole section analysisBenign breast tissueHeterogeneity of expressionSSTR2 levelsProgression of cancerTargeted therapyReceptor subtypesSomatostatin receptorsClinical significanceLymphatic elementsCo-localization techniquesCell line controlMalignant cellsSSTR2Breast tissueCancerPattern of expressionProtein expressionPeptide hormonesVessel compartmentReference standard curveSomatostatin
2006
Quantitative in Situ Assessment of the Somatostatin Receptor in Breast Cancer to Assess Response to Targeted Therapy With 111-in-Penetreotide
Chung G, Murren J, Rimm D. Quantitative in Situ Assessment of the Somatostatin Receptor in Breast Cancer to Assess Response to Targeted Therapy With 111-in-Penetreotide. 2006 DOI: 10.21236/ada455786.Peer-Reviewed Original ResearchBreast cancerTissue microarrayPredominant receptor subtypeBenign breast tissueSSTR2 levelsProgression of cancerSSTR2 expressionBone tumorsTargeted therapyReceptor subtypesSomatostatin receptorsClinical significanceCo-localization techniquesCell line controlMalignant cellsCancerBreast tissuePattern of expressionProtein expressionPeptide hormonesSomatostatinSSTR2ExpressionLarge proportionTherapy